Emerging Nondopaminergic Medications for Parkinson's Disease: Focusing on A2A?Receptor Antagonists and GLP1 Receptor Agonists

Pei Shang; Matthew Baker; Samantha Banks; 홍사익; 최두섭

doi:https://doi.org/10.14802/jmd.21035

추천

검색

자료유형: 학술저널

저자정보: Pei Shang (Mayo Clinic College of Medicine) Matthew Baker (Mayo Clinic College of Medicine) Samantha Banks (Mayo Clinic College of Medicine) 홍사익 (Mayo Clinic College of Medicine) 최두섭 (Mayo Clinic College of Medicine)

저널정보: 대한파킨슨병및이상운동질환학회 Journal Of Movement Disorders Journal Of Movement Disorders Vol.14 No.3

발행연도: 2021.9

수록면: 193 - 203 (11page)

DOI: https://doi.org/10.14802/jmd.21035

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Parkinson’s disease (PD) is a severe neurodegenerative disease characterized by classic motor features associated with the loss of dopaminergic neurons and appearance of Lewy bodies in the substantia nigra. Due to the complexity of PD, a definitive diagnosis in the early stages and effective management of symptoms in later stages are difficult to achieve in clinical practice. Previous research has shown that colocalization of A2A?receptors (A2AR) and dopamine D2?receptors (D2R) may induce an antagonistic interaction between adenosine and dopamine. Clinical trials have found that the A2AR antagonist istradefylline decreases dyskinesia in PD and could be used as an adjuvant to levodopa treatment. Meanwhile, the incretin hormone glucagon-like peptide 1 (GLP1) mainly facilitates glucose homeostasis and insulin signaling. Preclinical experiments and clinical trials of GLP1 receptor (GLP1R) agonists show that they may be effective in alleviating neuroinflammation and sustaining cellular functions in the central nervous system of patients with PD. In this review, we summarize up-to-date findings on the usefulness of A2AR antagonists and GLP1R agonists in PD management. We explain the molecular mechanisms of these medications and their interactions with other neurotransmitter receptors. Furthermore, we discuss the efficacy and limitations of A2AR antagonists and GLP1R agonists in clinical practice.

#A2A?receptor antagonist #?GLP1 receptor agonist #?Parkinson's disease

참고문헌 (127)

참고문헌 신청

Charvin D / 2018 / Therapeutic strategies for Parkinson disease : beyond dopaminergic drugs / Nat Rev Drug Discov 17:844

Bastide MF / 2015 / Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease / Prog Neurobiol 132:96~168

Moore TJ / 2014 / Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs / JAMA Intern Med 174:1930~1933

Chen JF / 2020 / The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease / Purinergic Signal 16:167~174

Chen JF / 2014 / Adenosine receptor control of cognition in normal and disease / Int Rev Neurobiol 119:257~307

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!